Back A A A Font Size Receive E-mail Alerts Press Releases

MicroPort® Attends CIT 2018


Suzhou, China – From March 22 to March 25, Shanghai MicroPort Medical (Group) Co., Ltd. ("MicroPort®") attended the China Interventional Therapeutics 2018 ("CIT 2018") that focuses on Cooperation, Innovation, and Transition. Original researches are presented in the form of oral and poster abstracts, late-breaking clinical trials, topic-oriented symposia, workshops, and concurrent sessions by global renowned cardiologists. The opening ceremony was chaired by Professor Bo Xu of Fuwai Hospital of Chinese Academy of Medical Sciences. Professor Gary S. Mintz, Professor Jean Fajadet, Academician Junbo Ge, Professor Yonghong Wang, and Professor Dafang Wang attended the meeting.
On March 23, MicroPort® hosted a Luncheon Satellite Symposium, chaired by Professor Shubin Qiao of Fuwai Hospital of Chinese Academy of Medical Sciences, Dr. LIEW Houng Bang of Queen Elizabeth Hospital of Malaysia, Professor Daxin Zhou of Zhongshan Hospital of Fudan University, Professor Lianjun Gao of the First Affiliated Hospital of Dalian Medical University, and Professor Chunguang Qiu of the First Affiliated Hospital of Zhengzhou University. The symposium features MicroPort® innovative products of coronary interventional, electrophysiological, cardiac valves, and pacemaker business segments, which attracted wide attention from the audience.
Professor Hongwei Pan of Hunan Provincial People's Hospital delivered a speech on "Introduction of the Complications of Radiographic Guide Wire in the Interventional Diagnosis and Treatment of Radial Artery and the Introduction of the Guide Wire of FireDragon™ Contrast Radiography". He said, FireDragon™ Guide Wire adopts unique design with better crossability than traditional coil angiography guide wire and improved safety compared to super smooth guide wire. Professor Feng Ze of Peking University People's Hospital presented on "Preliminary Application of Domestic 3D Navigation System in All Kinds of Complex Arrhythmia" in which he pointed out that Columbus™ 3D EP Navigation System ("Columbus™") is a leading domestically made 3D navigation system as it has superior performance in treating complex arrhythmia. Professor Daxin Zhou of Zhongshan Hospital of Fudan University introduced the clinical implementation of Vitaflow™ Transcatheter Aortic Valve and Delivery System. He said, VitaFlow™ is safe and stable, and no perivalvular leakage is observed in his clinical experience. Professor Zuoying Hu of Nanjing First Hospital delivered a speech on "A2D: A New Concept of Physiological Pacing" to introduce the development history and major products of physiologic pacemaker. During the symposium, the speakers and attendees had active discussion regarding product performance and surgical techniques. At the same time, the symposium was live broadcasted in MicroPort® headquarters, MicroPort® booth and Wechat to cover more audience.
The year 2018 marks the 20th anniversary of MicroPort®. Thus, the company displayed the development history of several business segments including cardiovascular, endovascular, electrophysiological, cardiac rhythm management, and surgical devices, based on the theme "MicroPort® 20 Years" in its CIT booth. Meanwhile, there was a stimulator in the booth for surgeons to have a better understanding of the product performance. Besides, in the VR experience center of MicroPort®, the visitor can experience the whole PCI procedure taking place in the coronary artery lesion from the perspective of the guide wire or stent. Besides, it provided visitors a more vivid understanding in coronary artery intervention devices as well as the features of Firehawk®.
In this congress, MicroPort® displayed several innovative achievements in the cardiovascular intervention industry. As a leading high-end medical device company in China and the world, MicroPort® is dedicated to providing patients with safe, effective and affordable cardiac interventional solutions through constant innovation and integrating global experts' techniques and experience.

About MicroPort®

MicroPort Scientific Corporation (the "Group") is a leading medical device company with business focusing on innovating, manufacturing, and marketing high-quality and high-end medical devices globally. With a diverse portfolio of products now being used at an average rate of one for every 12 seconds in thousands of major hospitals around the world, the Group maintains world-wide operations in a broad range of business segments including Cardiovascular, Orthopedic, Cardiac Rhythm Management, Electrophysiological, Endovascular, Neurovascular, Surgical, Diabetes Care and Endocrinal Management, and others. MicroPort® is dedicated to becoming a patient oriented global enterprise improve and reshape patient lives through application of innovative science and technology.

For more information, please refer to:

Forward-Looking Statements

Some information contained on this website contains forward-looking statements. These forward-looking statements include, without limitation, those regarding our future financial position, our strategy, plans, objectives, goals and targets, future developments in the markets where we participate or are seeking to participate, and any statements preceded by, followed by or that include the words "believe", "intend", "expect", anticipate", "project", "estimate", "predict", "is confident", "has confidence" and similar expressions are also intended to identify forward-looking statements. Such statements are based upon the current beliefs and expectations of MicroPort®'s management and are subject to significant risks and uncertainties. MicroPort Scientific Corporation undertakes no obligation to update any of the statements. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and other factors that could cause actual future results to differ materially from current expectations include, but are not limited to, general industry and economic conditions, PRC governmental policies and regulations relating to the medical device manufacturing industry, competition in the medical device manufacturing industry, our ability to develop new products and stay abreast of market trends and technological advances, our goals and strategies, our ability to execute strategic acquisitions of, investments in or alliances with other companies and businesses, fluctuations in general economic and business conditions in China.

This document is for information purposes only and does not constitute or form part of any offer or invitation to sell or the solicitation of an offer or invitation to purchase or subscribe for any securities of MicroPort Scientific Corporation, and no part of it shall form the basis of, or be relied upon in connection with, any agreement, arrangement, contract, commitment or investment decision in relation thereto whatsoever.

All rights reserved.
Copyright © 1998-2018 MicroPort Scientific Corporation

Leanne Li
Board Secretary and Vice President of Corporate General Affairs
MicroPort Scientific Corporation
Tel: (86)(21) 38954600-6953


[Prev]:CIT 2018: MicroPort® Hosts Twilight Symposium "MicroPort® 20 Years – From Firehawk® to Firesorb®"
[Next]:MicroPort® Completes the Acquisition of the Cardiac Rhythm Management Business from LivaNova